Industry Hires House&#39;s Author of Drug Benefit
692785
Representative Billy Tauzin, a principal author of the new Medicare drug law, will become president of the Pharmaceutical Research and Manufacturers of America, the chief
300953
Retiring US Rep. Billy Tauzin, former House Commerce Committee chairman and a principal architect of the prescription drug benefit for Medicare, will become the new president and CEO of
454410
Editors of the world&#39;s leading medical journals said yesterday that drug companies should disclose more information about studies of new medicines.
21611
One undervalued drug developer may be on the cusp of greatness.
639887
Learn a lesson or two from the drugmaker's dance with the FDA.
613309
The former chairman of the U.S.  House of Representatives Energy and Commerce Committee, who  earlier this year ended negotiations to head the pharmaceutical  industry's top lobby after critics questioned the ethics of the  move, has now accepted the post, the group said on Wednesday.
656231
The U.S. House of Representatives  approved a bill on Wednesday aimed at strengthening Food and  Drug Administration drug safety oversight and raising  pharmaceutical industry fees that help speed product reviews.
231778
Some pharma industry players decide to integrate crowdsourcing into R&amp;D to help reduce the high costs of developing new medicines. Assignment Zero interviews Dr. Alpheus Bingham of Innocentive for insights into how it works.
66629
Americaâs pharmaceutical industry is putting out an advisory about the latest potential threat to its health: Michael Moore. Moore, the filmmaker whose targets have included General Motors
211373
The new Merck/Merial Manual for Pet Health: Home Edition is a 1,345-page book likely to find readership in an animal-crazed nation.
344958
A top Republican lawmaker raised concerns about the US Food and Drug Administration&#39;s ability to monitor drug safety following Merck &amp; Co.
764344
The anti-industry crusader targets pharmaceuticals.
408527
Suzy Welch, a former editor of the Harvard Business Review and the wife of John F. Welch Jr., the former chief executive of General Electric, has agreed to sell the rights to her book â10-10-10â to Scribner, an imprint of Simon & Schuster. A person involved in the negotiations said that Scribner paid Ms. Welch a price in the seven figures for world and audio rights to the book. Based on an article Ms. Welch wrote for O, the Oprah Magazine, in 2006, the book offers strategies for making decisions in which people think about what the consequences of a decision will be in 10 minutes, 10 months and 10 years. Robert Barnett, a Washington lawyer, negotiated the deal on behalf of Ms. Welch. Nan Graham, editor in chief of Scribner, will edit the book with Samantha Martin. Ms. Welch, who wrote the best-selling âWinningâ with Mr. Welch, said she originally thought there wasnât a book beyond the article. But, she said, âI began to encounter this hunger for people who were using it to play out its nuances.â She said the book would include examples from her own life as well as others she has observed using the â10-10-10â process. Susan Moldow, publisher of Scribner, said that although Ms. Welchâs article might seem sufficient for those who wanted to know about the strategy, Ms. Moldow believed the book would sell well. âThe Scarsdale Diet fit on a Xerox-ed sheet that you could fit on the front of a refrigerator,â Ms. Moldow said. âAnd it sold millions and millions of copies. Itâs often true that when something strikes an immediate âAha!,â you really want to have time to meditate on it and try to get to know more about it.â.
129855
Dr. David Graham, the Food and Drug Administration scientist who publicly criticized the agency&#39;s approach to drug safety during a congressional hearing last week, said
430204
Dr. David J. Graham, the FDA drug safety reviewer who sounded warnings over five drugs he felt could become the next Vioxx has turned to a Whistleblower protection group for legal help.
328455
One of the first researchers to link the popular prescription painkillers Vioxx and Celebrex to heart problems blamed aggressive advertising for escalating public health risks and called for enabling the government to require better clinical trials to prevent future drug disasters.
91514
A veteran U.S. Food and Drug  Administration scientist will unveil new data on Thursday  before an expert panel charged with determining whether pain  relievers similar to Merck & Co. Inc.'s now-withdrawn Vioxx  should remain on the market.